早期霍奇金淋巴瘤的治疗推荐
过去数十年,联合模式治疗是早期霍奇金淋巴瘤的标准选择。因成功率高且存在晚期毒性风险,近期临床试验聚焦于减轻治疗负担。放疗野和剂量及化疗周期数已成功减少,尤其对预后良好早期患者。但治疗强度降低对第二恶性肿瘤发生率的影响仍不明确。
要点
- 放疗野和剂量及化疗周期数已成功减少,尤其对预后良好早期患者。
- 治疗强度降低对第二恶性肿瘤发生率的影响仍不明确。
- PET-CT已成为分期和治疗结束评估的重要工具,2周期ABVD后PET与最终结局相关。
核心结论
- 放疗野和剂量及化疗周期数已成功减少,尤其对预后良好早期患者,但治疗强度降低对第二恶性肿瘤发生率的影响仍不明确。
主要发现
- 放疗野和剂量及化疗周期数已成功减少,尤其对预后良好早期患者。
- PET-CT已成为疾病分期和治疗结束评估的非常重要的工具。
- 2周期ABVD后进行的PET与最终结局相关,近期随机临床试验评估了基于2或3周期ABVD后PET反应的个体化治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Combined modality treatment has been the standard option for the treatment of early stage Hodgkin lymphoma for several decades. Because of the high success rate and the risk of late toxicities, recent clinical trials have focused on reducing the treatment burden. Field and dose of radiotherapy, and number of cycles of chemotherapy have been successfully reduced, particularly for favourable early stage patients. However, the impact of these treatment reductions on the rate of secondary malignancies remains still unclear. Positron emission tomography-computed tomography (PET-CT) scanning has emerged as a very important tool for disease staging and end of treatment assessment. Interestingly, a PET performed after 2 cycles of ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) has been correlated with final outcome and was recently evaluated in a randomized clinical trial to evaluate individualized therapy based on PET response after 2 or 3 cycles of ABVD. These trials aimed to identify good prognosis (early PET-negative) patients who could be spared radiotherapy, but also patients with a bad prognosis (early PET-positive) who need more intensive treatment. More recently, new drugs, such as brentuximab vedotin and checkpoint inhibitors, have shown efficacy in relapsed/refractory patients and are currently under evaluation in early stage patients.
引用
- Depaus J, Delcourt A, André M, et al. Therapeutic recommendations for early stage Hodgkin lymphomas. Br J Haematol. 2018. PMID: 30485401. doi:10.1111/bjh.15623
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。